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Introduction
Methylmalonic acidurias (MMAurias) are a heterogeneous
group of inherited metabolic disorders (IMDs) leading to
increased urinary methylmalonic acid excretion.1 The
aetiology of MMAurias includes isolated and combined
with hyperhomocystenaemia.2 Isolated MMAuria is
caused by complete or partial deficiency of the enzyme
methylmalonyl-CoA mutase (MCM) usually with normal
serum methionine concentration.3,4 In intracellular
Cobalamin-related remethylation disorders (Cb1-RD),
MMAuria and hyperhomocystenaemia are present. A
tricarboxylic acid (TCA) cycle disorder; Succinate-CoA
ligase (SUCL) also present as MMAuria but with TCA cycle
markers (fumarate, succinate, malate, and 2-
ketoglutarate) identified on urine chromatography.5
Vitamin B12 deficiency is a non-IMD cause of MMAuria
combined with hyperhomocytenaemia.6,7
The age of presentation of MMAurias varies from neonatal
period to adulthood. Patients present with vomiting,
dehydration, hypotonia, lethargy, encephalopathy,
seizures, intellectual disability (ID), psychomotor
regression, movement disorders and failure to thrive.8,9
MMA is identified as the most common organic acidemia
in Asians in the sub-continent in literature.10,11 Reports
published from Pakistan have shown high incidence of
MMA but the aetiology of MMAurias has not been
described.12,13 The current study was planned to
determine the frequency of disorders leading to MMAuria
diagnosed by urine organic acid (UOA) analysis and the
outcome.
Patients and Methods
The cross-sectional study was conducted from January
2013 to April 2016 at Biochemical Genetic Laboratory
(BGL) in the Section of Chemical Pathology, Department
of Pathology and Laboratory Medicine and Department of
Paediatrics and Child Health, Aga Khan University (AKU),
Karachi. It comprised patients diagnosed with MMAurias
based on UOA analysis. Peaks were categorised into
marked, moderate and small based on comparison with
internal standard. Cases with very small peaks of
methylmalonic acidemia (MMA) compared to internal
standard, on UOA chromatograms were excluded. Clinical
history and biochemical data was collected from the BGL
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Objective: To determine the frequency of disorders leading to methylmalonic acidurias.
Methods: This cross-sectional study was conducted from January 2013 to April 2016 at the Aga Khan University
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requisition forms. Biochemical data related to UOA,
plasma amino acid (PAA), serum folic acid (FA), serum B12,
plasma total homocysteine (tHcy), plasma lactate (LA),
plasma ammonia (NH3), blood pH, and mean corpuscular
volume (MCV) were reviewed. Ethical exemption was
obtained from the institutional ethical review committee.
For UOA analysis, spot-urine samples were collected
without preservative, while for PAA analysis, blood
samples were collected in lithium heparin tubes. Samples
were separated and stored at -20°C until analysis.
Quantitative analysis of PAA was performed by cation
exchange-high performance liquid chromatography on
Biochrom 30+ Amino acid analyser (Biochrom, US).
Qualitative evaluations of organic acids in urine was
performed by gas chromatography mass spectrometry
(GCMS) on Agilent GCMS system (Agilent Technologies,
US) using ethyl acetate, derivatisation by bis
(trimethylsilyl) acetamide compound and internal
standard in UOA testing used is 3,3 dimethyl glutaric acid.
Semi quantitation of methylmalonate, methyl citrate, 3
hydroxy (3 OH) isovalerate and tiglylglycine was done
using formula: area under curve of metabolite/area under
curve of internal standard × concentration of internal
standard. It was reported in pseudounits (PU).14
During the period of study, BGL also participated in
proficiency testing programme for UOA and PAA by
European Research Network for evaluation and
improvement of screening, diagnosis and treatment of
Inherited Disorders of Metabolism (ERNDIM, UK) and
College of American Pathologists (CAP) for all other
analytes.
Organic acid chromatograms of all patients with
MMAurias were critically reviewed by a biochemical
pathologist and a metabolic physician. Cases with very
small peaks of methylmalonic acid were excluded
(Figure-1).
All patients with MMAuria were grouped as below based
on the result of biochemical investigations:
MMA due to methylmalonyl CoA mutate deficiency —
normal FA, tHcy, B12 and methionine; Cb1-RD defects —
high tHcy, low plasma methionine, normal serum B12
and FA; 
a. SUCL deficiency — presence of fumarate, succinate, 2-
ketoglutarate and malate with MMAuria; 
b. B12 deficient — serum B12 <200pg/ml; and nonspecific
MMAuria — tHcy, FA and B12 data not available.
For assessing the clinical outcome, medical charts of
patients followed by metabolic physician were reviewed
while outside referrals followed by general paediatrician
were contacted by phone and history of clinical
presentation, details of treatment received and mortality
was collected on a pre-structured questionnaire.
Frequency and percentage was generated for gender,
while median with interquartile ranges (IQR) were
calculated for quantitative parameters. Frequency and
percentage of patients with different types of MMAurias
was generated. Comparison between Cb1-RD defects,
MMA and nonspecific MMAuria was performed by Kruskal
Wallis test, taking p <0.05 as significant. B12 and SUCL
deficiencies were excluded from comparison analysis due
to the small sample size. SPSS 19 was used for data
analysis.
Results
Of the 1,778 patients who underwent UOA analysis,
50(2.81%) were detected with MMAurias. However,
9(18%) patients with small peaks of methylmalonate were
excluded. Frequency of MMAuria, as such, was 41(2.3%).
Of these, 21(51.2%) samples were received from Sindh,
14(34%) from Punjab, 5(12%) from Khyber Pakhtunkhwa
(KP), and 1(2.43%) from Baluchistan. Of those detected
with MMAuria, median age at the time of diagnosis was
11.5 (IQR: 6-41.5) months; 20(48.7%) being female.
Lethargy and ID were the most common clinical features,
followed by failure to thrive, seizures, hypotonia and
vomiting. Metabolic acidosis, anemia, hyperammonemia,
lactic acidosis and hyperhomocytenemia were common
biochemical findings (Table).
The median MMA levels on UOA were 352 PU (IQR: 107.7-
1229). Methylcitrate was detected in 32(78%) patients, 3-
OH isovalerate in 38(93%), 3-OH propionate 25(60%),
tiglylglycine in 16(35%) and propionylglycine in 4(7.5%).
Hypomethionenaemia was detected in 18(45%) and
hyperglycinaemia favouring MMA was detected in
3(7.5%) patients.
Median age of presentations in patients with Cb1-RD
defects, MMA and nonspecific MMAurias were 96 months
(IQR: 19-144), 11.5 months (IQR: 5.8-15.5) and 6 months
(IQR: 2.7-16.2) respectively (p<0.001) (Figure-1). Lethargy,
seizures, developmental delay and mental retardation
were statistically significantly (p <0.05) in Cb1-RD defects,
MMA and nonspecific MMAuria (Figure-2).
Among the biochemical parameters in the MMA, Cb1-RD
and non-specific MMAuria groups, tHcy, MCV,
methylmalonate, 3OH isovalerate, glycine and alanine
were significantly different (p<0.05). 
Besides, 19(46.34%) patients were followed by metabolic
physician at AKUH and the remaining 22(53.66%) were
Vol. 68, No. 4, April 2018
Diagnostic dilemma of patients with methylmalonic aciduria: Experience from a tertiary care centre in Pakistan 511
J Pak Med Assoc
512 H. Majid, L. Jafri, A. H. Khan, et al
Table: Biochemical Parameters [Median (Interquartile range)].
Biochemical Parameter                                                     Total Patients                                Cb1-RD def                                       MMA                           Non-specific MMAuria                  P-value
(Reference intervals)                                                                   n=41                                                n=12                                             n=9                                             n=16
Blood pH (7.35-7.45)                                                               7.32 (7.16-7.46)                             7.48 (7.44-7.49)                         7.27 (7.15-7.33)                          7.33 (7.1-7.47)                               0.152
Lactic Acid (0.3-11 mmol/l)                                                      2.7 (1.48-9.2)                                     1.6 (1.2-3)                                 3.3 (1.6-22.1)                           7.45 (1.78-19.5)                              0.316
Plasma Ammonia (Neonate <100 µmol/l,
>1 month <40 µmol/l)                                                         56.6 (39.8-90.2)                             43.6 (35.9-75.5)                        68.7 (15.3-136.1)                       85.5 (63.1-162.8)                            0.164
MCV (Age specific Reference Range)                                 86.7 (80.3-102.3)                               101 (83-108)                                82 (80-84.7)                                          NA                                           0.073
Serum Folic Acid (2.6-12.2 ng/ml)                                          20 (13.8-24)                                    24 (19.8-24)                             12.9 (10.6-19.3)                                      NA                                           0.053
Vitamin B12 (>201pg/ml)                                                      750 (250-1057)                            946 (412.7-1140)                          276 (201-925)                                        NA                                            0.14
Total Homocysteine (5-12 umol/l)                                     58.6 (16.8-141.2)                          85.6 (58.6-197.5)                          9.5 (4.2-16.7)                                         NA                                           0.001
Urine Methylmalonate                                                           352 (107.7-1229)                             143 (83.4-265)                          1184 (460-3655)                         503 (107-1616)                              0.046
Urine Methyl citrate                                                                42.7 (18.7-125.5)                             31 (5.8-160.5)                               40 (15-274)                                  56 (29-184)                                  0.554
Urine 3 OH isovalerate                                                              12.8 (6.4-81.7)                                  6.1 (3.1-8.9)                               16 (12.5-346)                                  21 (8-91)                                    0.024
Urine Tiglylglycine                                                                       1.2 (0.42-7.5)                                   0.7 (0.3-3.6)                                  11 (0.6-18)                                1.4 (0.18-5.8)                                0.296
Plasma Methionine                                                                        7 (4- 11.5)                                         7 (4 - 10)                                      5 (4-11.5)                                  9.5 (6.2-14.5)                                0.521
Plasma Glycine                                                                             259 (170-348)                                268 (184-338)                           179 (122.5-264)                           383 (256-553)                               0.032
Plasma Alanine                                                                            216 (155-340)                                300 (226-380)                              161 (55-206)                              170 (136-279)                               0.008
MCV: Mean corpuscular volume. Cb1-RD:  Cobalamin remethylation defects. MMA: Methylmalonic acidemia. PU: Pseudounits.
UOA: Urine organic acid. FSMP: Food for special medical purpose.
Cb1-RD: Cobalamin remethylation defects. SSUL: Succinyl coenzyme A synthetase
MMA: Methylmalonic acidemia.
Figure-1: Flowchart showing Frequency and Outcome of patients with MMAuria.
followed in different clinical settings by general
paediatricians. Among those under care of metabolic
physicians, 11(50%) were Cb1-RD, 6(27.27%) were MMA
and 1(4.5%) with SUCL and B12 deficiency, respectively.
All patients with non-specific MMAurias with incomplete
biochemical evaluation were outside referrals. Mortality
in the outside referrals was high compared to the group
followed by metabolic physicians [9(43%) vs 1(5%)]. In
non-specific MMAuria group treatment was started in
7(44%) patients only.
Discussion
MMAuria is one of the common biochemical features
observed in the UOA analysis in our lab. Evaluation of the
disorders leading to MMAuria is imperative for the correct
diagnosis, appropriate treatment and better outcome of
the patients.15,16 Biochemical parameter including tHcy,
serum B12, FA and PAA analysis is essential for the
diagnostic evaluation of MMAuria.17,18 In the present
study ID was common in patients with Cb1-RD defects
compared to other patients. This could be due to the
younger age of presentation in MMA deficiency group,
when ID is difficult to access clinically. Methylmalonate
and other metabolites on UOA were higher in the MMA
than in Cb1-RD defects. The tHcy levels were high in Cb1-
RD patients while glycine was higher in MMA patients.
Among the 16 patients with MMAuria referred from outside,
complete biochemical findings were not available as
patients were not further investigated to determine the
aetiological defect. The
treatment prescribed to this
group pointed to the lack of
understanding about the
difference in the treatment of
MMA, Cb1-RD and SUCL
deficiency. High mortality was
observed in such patients.
Both MMA and Cb1-RD are
treatable disorders, if
diagnosed early and treated
appropriately.19-21 The reason
for this high mortality is likely
inadequate and incomplete
evaluation for the aetiology of
MMAuria leading to
inappropriate treatment.
These findings advocate the
need to improve health
services and education of
healthcare providers to
advance the understanding of
IMDs, training of human
resources, expansion of and
equality of access to diagnostic tests.
Lack of enzymatic analysis for MMA, complementation
studies for Cb1-RD and molecular studies of the patients
due to the local non-availability of these advance tests is
a limitation of our study. We were also unable to
categorise 16 patients into an aetiological classification of
MMAuria due to the non-availability of the relevant
biochemical parameters.
Conclusion
MMAuria is a biochemical finding present in patients with
MMA, Cb1-RD, SUCL deficiency and serum B12 deficiency.
Thus all patients with MMAuria should be further
investigated with PAA, tHcy, B12 and FA levels for the
correct diagnosis. A correct diagnosis allows clinicians to
prescribe appropriate treatment, leading to better
outcome.
Disclaimer: The abstract was presented in the Society for
Inborn Errors of Metabolism Conference, 2016, at Rome,
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